Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Novel Bone Marrow/HSC-Targeted, Megakaryocyte-Derived Extracellular Vesicle Delivery Modality for In Vivo Gene Therapy

Laura R Goldberg, Qiuyan W Ma, Navdeep Malik, Daniel Bode, Samik Das, Will Thompson, Jenna C Harris, Joseph R Inigo, Pragati Jain, Emily S Day, David M Raiser, Sedattin S Ozturk, Eleftherios T Papoutsakis, Iain R Thompson, Jonathan N. Thon

Blood (2023) 142 (Supplement 1): 2253.

https://doi.org/10.1182/blood-2023-179450

Published: 2023

Journal Articles

Clonal hematopoiesis, myeloid disorders and BAX -mutated myelopoiesis in patients receiving venetoclax for CLL

Piers Blombery, Thomas E. Lew, Michael A. Dengler, Ella R. Thompson, Victor S. Lin, Xiangting Chen, Tamia Nguyen, Ashish Panigrahi, Sasanka M. Handunnetti, Dennis A. Carney, David A. Westerman, Constantine S. Tam, Jerry M. Adams, Andrew H. Wei, David C. S. Huang, John F. Seymour, Andrew W. Roberts, Mary Ann Anderson

Blood (2022) 139 (8): 1198–1207.

https://doi.org/10.1182/blood.2021012775

Published: 2022

Includes: Supplemental data

Journal Articles

Expert Curation of Somatic FLT3 Variants By the Clingen Somatic Hematologic Cancer Taskforce (ClinGen HCT)

Blood (2021) 138 (Supplement 1): 4387.

https://doi.org/10.1182/blood-2021-153546

Published: 2021

Journal Articles

Expert Curation of Somatic Variants in Hematological Malignancies By the Clingen Somatic Hematological Cancer Taskforce (ClinGen HCT)

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-143028

Published: 2020

Journal Articles

Mutational and Copy Number Profiling of Circulating Tumor DNA in Acute Myeloid Leukemia Using Targeted Next Generation Sequencing

Ing Soo Tiong, MBBS,FRACP,FRCPA, Clarissa Wilson, BSc,MSc, Satwica Yerneni, MS, John Markham, Karen Dun, BSc,FHGSA, Ashish Bajel, FRACP, Ella R Thompson, PhD BSc, David Alan Westerman, MBBS, FRCPA, FRACP, Piers Blombery, MBBS

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-138933

Published: 2020

Journal Articles

Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-136872

Published: 2020

Journal Articles

BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia

Piers Blombery, MBBS, Ella R Thompson, PhD BSc, Xiangting Chen, PhD, Tamia Nguyen, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, David Alan Westerman, MBBS, FRCPA, FRACP, John F. Seymour, Constantine S. Tam, MBBS, MD, Michael A Dengler, PhD, David C.S. Huang, MBBS MRCP PhD, Andrew Wei, MBBS,PhD, Andrew W Roberts, MBBS

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-137775

Published: 2020

Journal Articles

High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia

Ella R Thompson, PhD BSc, Tamia Nguyen, Yamuna Kankanige, PhD, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Rachel Thijssen, PhD, Paul Sung-Hao Yeh, MBBS, FRCPA, FRACP, Constantine S. Tam, MBBS, MD, John F. Seymour, Andrew W Roberts, MBBS, David Alan Westerman, MBBS, FRCPA, FRACP, Piers Blombery, MBBS

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-137411

Published: 2020

Journal Articles

Neoantigens Are Typically Associated with Intact HLA Class I Presentation in Early-Stage Follicular Lymphoma

Hennes Tsang, BSc, Ann-Marie Patch, PhD, Colm Keane, MD, Soi C. Law, PhD, Jay Gunawardana, PhD, Piers Blombery, MBBS, Ella R Thompson, PhD BSc, Muhammed B. Sabdia, Lilia Merida De Long, Clemence J Belle, Karthik Nath, MBBS, Joshua W.D. Tobin, MD, Stephen H Kazakoff, PhD, John F. Seymour, Michael MacManus, Maher K. Gandhi, PhDFRACP,FRCPath

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-135954

Published: 2020

Journal Articles

Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax

Piers Blombery, Ella R. Thompson, Tamia Nguyen, Richard W. Birkinshaw, Jia-nan Gong, Xiangting Chen, Michelle McBean, Rachel Thijssen, Thomas Conway, Mary Ann Anderson, John F. Seymour, David A. Westerman, Peter E. Czabotar, David C. S. Huang, Andrew W. Roberts

Blood (2020) 135 (10): 773–777.

https://doi.org/10.1182/blood.2019004205

Published: 2020

Includes: Supplemental data

Journal Articles

FVIII Proteins with a Modified Immunodominant T-Cell Epitope Exhibit Reduced Immunogenicity and Normal Procoagulant Activity

Ruth A. Ettinger, PhD, Joseph A. Liberman, PhD, Devi Gunasekera, BSSM, Eddie A. James, PhD, Arthur R. Thompson, MD PhD, Kathleen P. Pratt, PhD

Blood (2017) 130 (Supplement 1): 179.

https://doi.org/10.1182/blood.V130.Suppl_1.179.179

Published: 2017

Journal Articles

T cells from hemophilia A subjects recognize the same HLA-restricted FVIII epitope with a narrow TCR repertoire

Ruth A. Ettinger, Pedro Paz, Eddie A. James, Devi Gunasekera, Fred Aswad, Arthur R. Thompson, Dana C. Matthews, Kathleen P. Pratt

Blood (2016) 128 (16): 2043–2054.

https://doi.org/10.1182/blood-2015-11-682468

Published: 2016

Includes: Supplemental data

Journal Articles

Factor VIII Proteins Having a Rationally Modified, Immunodominant T-Cell Epitope Demonstrate Normal Procoagulant Activity, Bind To VWF With High Affinity, and Are Markedly Less Stimulatory To FVIII-Specific Human T Cells

Ruth A. Ettinger, Ph.D., Eddie A. James, Ph.D., Komal Puranik, M.Sc., Arthur R. Thompson, M.D., Ph.D., Dana C. Matthews, M.D., Kathleen P. Pratt, Ph.D.

Blood (2013) 122 (21): 574.

https://doi.org/10.1182/blood.V122.21.574.574

Published: 2013

Journal Articles

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

Samantha C. Gouw, H. Marijke van den Berg, Johannes Oldenburg, Jan Astermark, Philip G. de Groot, Maurizio Margaglione, Arthur R. Thompson, Waander van Heerde, Jorien Boekhorst, Connie H. Miller, Saskia le Cessie, Johanna G. van der Bom

Blood (2012) 119 (12): 2922–2934.

https://doi.org/10.1182/blood-2011-09-379453

Published: 2012

Includes: Supplemental data

Journal Articles

Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients

Blood (2012) 119 (3): 666–672.

https://doi.org/10.1182/blood-2011-07-367003

Published: 2012

Includes: Supplemental data

Journal Articles

Factor VIII Mutation and Desmopressin-Responsiveness in 63 Patients with Mild Hemophilia A

Danielle Nance, MD, Shelley Nakaya Fletcher, Doug C Bolgiano, MS, Arthur R. Thompson, MD, PhD, Neil C. Josephson, MD, Barbara A. Konkle, M.D.

Blood (2011) 118 (21): 1203.

https://doi.org/10.1182/blood.V118.21.1203.1203

Published: 2011

Journal Articles

Risk Factors for Inhibitor Development in Mild and Moderate Hemophilia A: A Case-Control Study.

Christine L Kempton, MD, MSc, J. Michael Soucie, Ph.D, Connie H. Miller, PhD, Craig Hooper, PhD, Miguel A. Escobar, MD, Mark T. Reding, MD, Alice J. Cohen, MD, Nigel S. Key, MBChB, Arthur R. Thompson, M.D., Ph.D., Marilyn J. Manco-Johnson, Thomas C. Abshire, MD

Blood (2009) 114 (22): 3184.

https://doi.org/10.1182/blood.V114.22.3184.3184

Published: 2009

Journal Articles

Reduced Immunogenicity of FVIII Peptides by Rational Modifications of An Immunodominant T-Cell Epitope.

Ruth A. Ettinger, Ph.D., Joseph A. Liberman, B.S., Douglas C. Bolgiano, M.S., Arthur R. Thompson, M.D., Ph.D., Kathleen P. Pratt, Ph.D.

Blood (2009) 114 (22): 220.

https://doi.org/10.1182/blood.V114.22.220.220

Published: 2009

Journal Articles

CD4 + FOXP3 + regulatory T cells confer long-term regulation of factor VIII–specific immune responses in plasmid-mediated gene therapy–treated hemophilia mice

Carol H. Miao, Benjamin R. Harmeling, Steven F. Ziegler, Benjamin C. Yen, Troy Torgerson, Liping Chen, Roger J. Yau, Baowei Peng, Arthur R. Thompson, Hans D. Ochs, David J. Rawlings

Blood (2009) 114 (19): 4034–4044.

https://doi.org/10.1182/blood-2009-06-228155

Published: 2009

Includes: Supplemental data

Journal Articles

Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti–factor VIII immune responses

Ruth A. Ettinger, Eddie A. James, William W. Kwok, Arthur R. Thompson, Kathleen P. Pratt

Blood (2009) 114 (7): 1423–1428.

https://doi.org/10.1182/blood-2009-01-200725

Published: 2009

NARROW

Novel Bone Marrow/HSC-Targeted, Megakaryocyte-Derived Extracellular Vesicle Delivery Modality for In Vivo Gene Therapy

Clonal hematopoiesis, myeloid disorders and BAX -mutated myelopoiesis in patients receiving venetoclax for CLL

Expert Curation of Somatic FLT3 Variants By the Clingen Somatic Hematologic Cancer Taskforce (ClinGen HCT)

Expert Curation of Somatic Variants in Hematological Malignancies By the Clingen Somatic Hematological Cancer Taskforce (ClinGen HCT)

Mutational and Copy Number Profiling of Circulating Tumor DNA in Acute Myeloid Leukemia Using Targeted Next Generation Sequencing

Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia

BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia

High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia

Neoantigens Are Typically Associated with Intact HLA Class I Presentation in Early-Stage Follicular Lymphoma

Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax

FVIII Proteins with a Modified Immunodominant T-Cell Epitope Exhibit Reduced Immunogenicity and Normal Procoagulant Activity

T cells from hemophilia A subjects recognize the same HLA-restricted FVIII epitope with a narrow TCR repertoire

Factor VIII Proteins Having a Rationally Modified, Immunodominant T-Cell Epitope Demonstrate Normal Procoagulant Activity, Bind To VWF With High Affinity, and Are Markedly Less Stimulatory To FVIII-Specific Human T Cells

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients

Factor VIII Mutation and Desmopressin-Responsiveness in 63 Patients with Mild Hemophilia A

Risk Factors for Inhibitor Development in Mild and Moderate Hemophilia A: A Case-Control Study.

Reduced Immunogenicity of FVIII Peptides by Rational Modifications of An Immunodominant T-Cell Epitope.

CD4 + FOXP3 + regulatory T cells confer long-term regulation of factor VIII–specific immune responses in plasmid-mediated gene therapy–treated hemophilia mice

Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti–factor VIII immune responses

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only